High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes.

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-04-01 DOI:10.1158/2159-8290.CD-24-1509

Marina N Sharifi, Jamie M Sperger, Amy K Taylor, Katharine E Tippins, Shannon R Reese, Viridiana Carreno, Katherine R Kaufmann, Alex H Chang, Luke A Nunamaker, Charlotte Linebarger, Leilani Mora-Rodriguez, Jennifer L Schehr, Hannah M Krause, Kyle T Helzer, Matthew L Bootsma, Grace C Blitzer, John M Floberg, Christos E Kyriakopoulos, Hamid Emamekhoo, Elisabeth I Heath, Meghan Wells, Scott T Tagawa, Martin Sjöström, Atish D Choudhury, Menggang Yu, Andrew J Armstrong, Dana E Rathkopf, Himisha Beltran, Peter S Nelson, Felix Y Feng, Scott M Dehm, David Kosoff, Xiao X Wei, Rana R McKay, Shuang G Zhao, Joshua M Lang

引用次数: 0

Abstract

Significance: Treatment resistance remains a universal driver of lethal metastatic prostate cancer, associated with acquired genomic alterations and lineage transitions. Using a novel high-purity CTC isolation approach for CTC transcriptional profiling, we identified four lineage phenotypes differentially associated with prognosis in metastatic prostate cancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.